[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Verastem, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":171},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,70,83,103,112,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054140","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pancreatic-cancer-100054140",false,"NCT07644559","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)","Inclusion Criteria:\n\n* Histopathology confirmed PDAC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\nAdequate organ function\n\nVS-7375 + cetuximab (2L PDAC) :\n\n-Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months\n\nVS-7375 + cetuximab (1L PDAC) :\n\n-Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease\n\nExclusion criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer",[26,27],"Pancreatic Ductal Adenocarcinoma (PDAC)","G12D Mutated KRAS",[29,30,31,32,33,34,35],"KRAS G12D mutation","KRAS","PDAC","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer","Pancreatic Neoplasms","RAS","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2026-06-16",{"date":44,"type":20},"2028-12",{"name":46,"class":47},"Verastem, Inc.","INDUSTRY",15,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":69},"100053529","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-non-small-cell-lung-cancer-100053529","NCT07659782","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","TARGET-D 202","Inclusion Criteria:\n\n* Histopathology confirmed unresectable locally advanced or metastatic NSCLC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n* Adequate organ function\n* Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.\n* Have documented disease progression during or following their most recent prior line of therapy.\n\nPatients with 2L\u002F3L on stable or preferred dose:\n\n* Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n\nPatients with 2L-4L with brain metastases:\n\n* Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n* Have asymptomatic and untreated brain metastases\n* At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply",{"count":58,"type":20},105,[23],"This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer",[62],"Non-Small Cell Lung Cancer","NOT_YET_RECRUITING",{"date":39,"type":40},{"date":66,"type":20},"2026-06",{"date":44,"type":20},{"name":46,"class":47},3,{"id":71,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":24,"conditions":74,"keywords":75,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":82},"100641650",{"count":19,"type":20},[23],[26,27],[29,30,31,32,33,34,35],"2026-07-01",{"date":78,"type":40},"2026-07-02",{"date":42,"type":40},{"date":44,"type":20},{"name":46,"class":47},14,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":102,"locationsCount":4},"100642372","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colorectal-cancer-100642372","NCT07659795","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)","TARGET-D 203","Inclusion Criteria:\n\n* Histopathology confirmed metastatic CRC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\n  2L+ patients:\n* Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma\n* Have documented disease progression during or following their most recent prior line of therapy\n* Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.\n\n  1L patients:\n* Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* Receipt of prior direct RAS inhibitor\n* Receipt of more than 1 investigational therapy\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply",{"count":92,"type":20},150,[23],"This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer",[96],"Colorectal Cancer","2026-06-15",{"date":99,"type":40},"2026-06-22",{"date":66,"type":20},{"date":44,"type":20},{"name":46,"class":47},{"id":104,"slug":4,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":60,"conditions":107,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":111,"locationsCount":4},"100641898",{"count":58,"type":20},[23],[62],{"date":99,"type":40},{"date":66,"type":20},{"date":44,"type":20},{"name":46,"class":47},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":82},"100594498","phase-1-a-phase-12-study-of-vs-7375-in-patients-with-kras-g12d-mutated-solid-tumors-100594498","NCT07020221","A Phase 1\u002F2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","A Phase 1\u002F2, Open-label Study of VS-7375, a KRAS G12D (ON\u002FOFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors","Key Inclusion Criteria:\n\n* Individuals ≥18 years of age.\n* Agreement to sign and date an informed consent form (ICF) approved by the Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC).\n* Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate organ function\n* Adequate cardiac function\n* Recovered from all AEs due to previous therapies to Grade ≤1 or baseline.\n* Agreement to use highly effective contraception\n\nKey Exclusion Criteria:\n\n* Underwent major surgical procedure as defined by the Investigator, other than for diagnosis, within 4 weeks prior to Cycle 1 Day 1,\n* Receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to Cycle 1 Day 1\n* Treatment with any investigational drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1.\n* History of treatment with direct and specific KRAS G12D inhibitors.\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.\n* Inability to swallow oral medications.\n* Evidence or history of uncontrolled, clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic disease\n* Individuals who are pregnant or breastfeeding.",{"count":120,"type":20},295,[122,23],"PHASE1","This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.",[32,125,96,126,27],"Non Small Cell Lung Cancer","Solid Tumor, Adult",[29,128,125,129,96,130,33,32,131,132,31,34,133,134,135,30,35],"Solid tumors","Lung Cancer","Metastatic Cancer","NSCLC","CRC","Colorectal Neoplasms","Lung Neoplasms","Gastrointestinal Neoplasms","2026-04-21",{"date":138,"type":40},"2026-04-22",{"date":140,"type":40},"2025-06-24",{"date":44,"type":20},{"name":46,"class":47},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100521683","phase-3-a-study-of-avutometinib-vs-6766--defactinib-vs-6063-in-recurrent-low-grade-serous-ovarian-cancer-100521683","NCT06072781","A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)","RAMP 301","Inclusion Criteria:\n\nPatients may be eligible for inclusion in the study if they meet the following criteria:\n\n1. Histologically proven LGSOC (ovarian, fallopian, peritoneal)\n2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test.\n3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole.\n4. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease.\n5. Measurable disease according to RECIST v1.1.\n6. An Eastern Cooperative Group (ECOG) performance status ≤ 1.\n7. Adequate organ function.\n8. Adequate recovery from toxicities related to prior treatments.\n9. For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive.\n10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.\n2. Co-existing high-grade serous ovarian cancer or mixed histology.\n3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors.\n4. History of prior malignancy with recurrence \\\u003C3 years from the time of enrollment.\n5. Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention.\n6. Symptomatic brain metastases requiring steroids or other interventions, known leptomeningeal metastases, or spinal cord compression.\n7. An active skin disorder that has required systemic therapy within one year of the first dose of study intervention.\n8. History of medically significant rhabdomyolysis.\n9. For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor.\n10. Symptomatic bowel obstruction within 3 months of the first dose of study intervention\n11. Concurrent ocular disorders.\n12. Concurrent heart disease or severe obstructive pulmonary disease.\n13. Active or past medical history of interstitial lung disease\u002Fpneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS).\n14. Subjects with the inability to swallow oral medications.\n15. History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned.\n16. Pregnant or breastfeeding.\n17. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.","FEMALE",{"count":153,"type":20},270,[155],"PHASE3","This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.",[158],"Low Grade Serous Ovarian Cancer",[158,30,160,161],"KRAS wt","KRAS mt","2026-04-01",{"date":164,"type":40},"2026-04-02",{"date":166,"type":40},"2024-03-18",{"date":168,"type":20},"2031-02-09",{"name":46,"class":47},106,""]